Talimogene Laherparepvec and Immune-Cell Populations in Non-Injected Lesions in Stage IIIB–IVM1c Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Talimogene Laherparepvec Upregulates Immune-Cell Populations in Non-Injected Lesions: Findings From a Phase II, Multicenter, Open-Label Study in Patients With Stage IIIB-IVM1c Melanoma
J Immunother Cancer 2021 Mar 01;9(3)e001621, J Malvehy, I Samoylenko, D Schadendorf, R Gutzmer, JJ Grob, JJ Sacco, KS Gorski, A Anderson, CA Pickett, K Liu, H GogasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.